EF Hutton Acquisition Co. I upgraded shares of OS Therapies (NYSE:OSTX – Free Report) to a strong-buy rating in a research note published on Tuesday, Zacks.com reports.
Separately, Brookline Capital Management upgraded OS Therapies to a strong-buy rating in a report on Thursday, August 22nd.
View Our Latest Stock Report on OSTX
OS Therapies Stock Performance
OS Therapies (NYSE:OSTX – Get Free Report) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.26) earnings per share (EPS) for the quarter. Sell-side analysts expect that OS Therapies will post -0.47 earnings per share for the current year.
OS Therapies Company Profile
OS Therapies Incorporated is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. Our mission is to address the significant need for new treatments in cancers of the bone in children and young adults.
Further Reading
- Five stocks we like better than OS Therapies
- Pros And Cons Of Monthly Dividend Stocks
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- How to Effectively Use the MarketBeat Ratings Screener
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- About the Markup Calculator
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
Receive News & Ratings for OS Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OS Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
